ARM Innovation Hub
RealVNC mid-banner general
RealVNC mid banner careers
Advertisement: EY Mid banner
Advertisement: Cambridge Network
Advertisement: EBCam mid banner
Barr Ellison Solicitors – commercial property
Advertisement: China mid banner
Mid banner advertisement: BDO
Advertisement: RSM
Advertisement: Mogrify
Advertisement: Simpsons Creative
22 May, 2020 - 10:32 By Tony Quested

Kinnon’s PredictImmune CEO role terminated

Mystery surrounds the abrupt departure of Paul Kinnon as CEO of Cambridge UK life science technology business PredictImmune.

Companies House reports: “Termination of appointment of Paul Kinnon as a director on 8 April 2020.”

Business Weekly has asked representatives of the company for a comment on the reasons for Kinnon’s departure but no response has been forthcoming. No mention of the development is made on the Babraham Research Campus company’s website.

PredictImmune develops pioneering tools for guiding treatment options in immune mediated diseases such as inflammatory bowel disease.The company won a Life Science Innovation accolade in the Business Weekly Awards in March 2019.

Kinnon joined the company as CEO in July 2018 having spent over 20 years in a number of successful executive positions in the United States.

Only last July under Kinnon’s leadership, PredictImmune raised $11 million in a Series B round to help further commercialise its technology. And in January, Kinnon announced that the company had entered into a commercial agreement with CCL, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK, Ireland (non-exclusive), the Middle East and the Balkans (exclusively).

The commercially focused agreement was designed to give increasing numbers of patients access to the world’s first, truly validated and CE-marked prognostic test for guiding treatment options in IBD (Crohn’s disease and ulcerative colitis). 

It enables both clinicians and patients to understand, at the point of diagnosis, the likely course of disease – differentiating between an aggressive or milder form.

Newsletter Subscription

Stay informed of the latest news and features